TickerWorth Open the interactive view →

MetLife, Inc. (MET) — Valuation Snapshot

Updated Nov 10, 2026 · bank / insurer · bank model (justified price-to-book) · descriptive, not a DCF, not advice

This is a bank / insurer / financial. A free-cash-flow DCF is structurally the wrong lens here (their debt and float are raw material, not financing), so we don't publish one. Instead we value it with a bank model — justified price-to-book, (ROE − g) ÷ (cost of equity − g), on a return on equity of 19.9% and a cost of equity of 8.5% — at about $102.28 a share ($87.66–$122.75 for a cost of equity one point either way), against a price of $101.67. A dividend-discount cross-check gives about $40.51, shown as a reference only. Every input is listed with its source; it is a model estimate, not a price target.
Price
$101.67
Market cap
$63,893,708,800
52-week high
$106.72
52-week low
$67.33
Currency
USD
Exchange
NYSE

MetLife, Inc. (MET) is a bank, insurer or other financial, and a free-cash-flow discounted-cash-flow (DCF) model is structurally the wrong lens for it: for these businesses debt and float are raw material, not financing. So we value it the way a bank is valued — on the return it earns on its book equity. Our bank model (justified price-to-book) puts it at about $102.28 a share, between $87.66 and $122.75 for a cost of equity one point either side of 8.5%, against $101.67 today. Every input is listed with its source. It is a model estimate, not a price target, and not investment advice.

On the numbers we do have, MET trades at a recent price of $101.67, a market capitalisation of about $63,893,708,800, sitting 87% of the way up its 52-week range ($67.33–$106.72), on the NYSE.

The standard alternative to a DCF is relative valuation — comparing MET's trading multiples against its direct industry peers. Here that gives P/E of 13.3× (richer than the peer median of 11.5×); Fwd P/E of 9.1× (cheaper than the peer median of 12.3×); P/B of 2.9× (richer than the peer median of 2.1×); P/S of 0.8× (cheaper than the peer median of 1.5×); Dividend yield of 2.3% (cheaper than the peer median of 1.3%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. MET shows a price-to-book (P/B) of 2.89 and book value of $35.22 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. MET is in an up-trend (price above both its 50- and 200-day averages), trading -4.7% from its 52-week high. Over the past year the stock is +27.3%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

To be exact about what this page is not: we are not saying the numbers for MET are unavailable. They are, and they are above. We are saying a discounted-cash-flow model is the wrong instrument for this kind of business, and publishing one anyway — because the inputs happen to exist — would be a precise answer to the wrong question. Refusing is the more useful answer, and it is the same rule we apply to every name in this category.

Relative valuation — MET vs peers

MultipleMETPeer median
P/E13.3×11.5×richer than
Fwd P/E9.1×12.3×cheaper than
P/B2.9×2.1×richer than
P/S0.8×1.5×cheaper than
Dividend yield2.3%1.3%cheaper than

Direct industry peers.

Asset / book-value view

Price / book (P/B)
2.89
Book value / share
$35.22

Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.

Price-based snapshot

50-day avg
$98.15
200-day avg
$86.28
From 52-wk high
-4.7%
1-year momentum
+27.3%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Compare MET with its peers

Companies people research alongside MET

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive MET view

A bank-model estimate beside an available-data snapshot — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.